Correlation of Memory CD8+ T Cells With Sepsis Severity and Mortality: a Single-center, Unblinded, Prospective, Non-interventional, Observational Study

Launched by WUHAN UNION HOSPITAL, CHINA · May 16, 2023

Keywords

ClinConnect Summary

This clinical trial is studying how certain types of immune cells, called CD8+ T cells, relate to the severity of sepsis and the chances of recovery in patients in the intensive care unit (ICU). Sepsis is a serious condition that occurs when the body has an extreme reaction to an infection, leading to organ damage and can often be life-threatening. The researchers want to understand how these immune cells change during the early stages of sepsis and how these changes might affect a patient's health and survival.

To participate in the study, individuals must be between 18 and 60 years old, and there are specific health conditions that could exclude them, such as certain cancers, autoimmune diseases, or recent treatments that affect the immune system. Participants will not be given any new treatments; instead, their health will be monitored, and researchers will take samples to study their immune cells. This study aims to gather important information that could help improve treatment for sepsis in the future. If you or a loved one are eligible and agree to participate, you will help advance our understanding of this serious condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients aged 18-60 years old without restriction of gender, race, religion, creed or nationality; No sedative drugs with elimination half-life were used before inclusion in the study; Patients and/or their family members know and agree to participate in the trial.
• Exclusion Criteria:
• • History of solid organ or bone marrow transplantation; Diseases that may affect immune-related indicators, such as autoimmune diseases such as rheumatoid arthritis and SLE, or hematological malignancies such as leukemia and lymphoma; Have received radiotherapy or chemotherapy within the past 30 days, or have received immunosuppressive drugs (tripterygium, mycophenolate, cyclophosphamide, FK506, etc); Pregnancy or lactation; Chronic nephrosis; Severe chronic liver disease (child-Pugh: Grade C); alcohol or opioid dependence, mental illness, or severe cognitive impairment; Patients and/or their family members refuse to participate in the trial.